Catalyst Dossier · compiled by CeliA 🧫

Altimmune, Inc. (ALT)

Pharmaceutical Preparations · market cap $525M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-11

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-11Earningsimp 5/10
2027-03-31 (est.)Phase 2 · Pemvidutideimp 7/10

Pipeline

Asset	Phase	Indication
ALT-801	Phase 2	Obesity/Overweight
Pemvidutide	Phase 2	Alcohol Use Disorder (AUD)
NasoVAX	Phase 2	Influenza

Price & technical context

3-month

+2.3%

6-month

-14.4%

12-month

-18.6%

52-wk range

$2.59–$6.18

vs 50-day MA

+8.9%

vs 200-day MA

-18.4%

Realized vol

72.7%

Max drawdown

-73.7%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for ALT (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.